GlassScriptPhysician profile
Sarah R Elneser
NPI 1407018088
$9,780.80
in general payments reported to CMS, 2019-2025
42 companies · $1,958 in 2025
The $1,958 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,450 · 2020: $276 · 2021: $170 · 2022: $1,448 · 2023: $1,961 · 2024: $2,518 · 2025: $1,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,330 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,329.51 |
| Education | $107.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,281.12 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,070.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,059.13 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $738.29 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $643.42 | 2019-2025 | |
| Astellas Pharma US INC | $604.54 | 2019-2025 | Veozah |
| Abbott Laboratories | $549.37 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.76 | 2019-2024 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $297.65 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Allergan, INC. | $292.33 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.56 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $266.71 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $220.31 | 2023-2025 | |
| Sage Therapeutics, LLC | $188.60 | 2024-2025 | Zurzuvae |
| Exact Sciences Corporation | $186.40 | 2023-2025 | Cologuard Collection Kit |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $144.48 | 2019-2023 | |
| Organon LLC | $142.44 | 2023-2025 | Nexplanon |
| Amgen INC. | $142.27 | 2019-2024 | Prolia, Evenity, Otezla |
| Currax Pharmaceuticals LLC | $123.97 | 2019-2024 | Contrave, Nexlizet, Nexletol |
| Sumitomo Pharma America, INC. | $106.03 | 2024-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.93 | 2024-2025 | Caplyta |
| Exeltis, USA INC. | $86.42 | 2022-2025 | Slynd |
| Biohaven Pharmaceutical Holding Company LTD. | $81.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $80.17 | 2022-2024 | Xarelto |
| Nalpropion Pharmaceuticals LLC | $69.42 | 2019 | |
| Corium, LLC | $65.99 | 2024 | Azstarys |
| Dexcom, INC. | $63.84 | 2022-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $63.71 | 2023-2024 | Yupelri |
| Agile Therapeutics, INC. | $62.05 | 2023-2024 | Twirla |
| Minerva Surgical, INC | $57.79 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.62 | 2019-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $54.85 | 2022 | |
| Therapeuticsmd, INC. | $52.23 | 2022 | |
| Hologic Sales and Service, LLC | $49.59 | 2023-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Ironshore Pharmaceuticals INC. | $31.57 | 2019 | |
| Abiomed | $26.27 | 2025 | |
| Kaleo, INC. | $26.17 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $25.59 | 2023 | |
| Novartis Pharmaceuticals Corporation | $23.28 | 2019 | |
| Gilead Sciences, INC. | $19.30 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.49 | 2024 | Voquezna |
| Intra-Sana Laboratories | $13.79 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Elneser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.